Abstract
BackgroundOvarian carcinosarcoma, which contains sarcomatous and carcinomatous components, is a very rare tumor. The carcinomatous component is often adenocarcinoma, and squamous cell carcinoma is extremely rare. We herein report a case of ovarian carcinosarcoma in which the carcinomatous component was squamous cell carcinoma.Case presentationA 68-year-old woman presented with a huge ovarian tumor with a clinical diagnosis of malignant tumor of the ovary. She underwent hysterectomy, bilateral adnexectomy, omentectomy and lymphadenectomy. Histologically, the tumor cells showed undifferentiated pleomorphic sarcoma as the sarcomatous component and squamous cell carcinoma as the carcinomatous component. The final diagnosis was ovarian carcinosarcoma with squamous cell carcinoma in the carcinomatous component, stage IIIA1. Postoperatively, the patient was treated with six cycles of combination chemotherapy with paclitaxel and carboplatin as adjuvant therapy. The patient was free of disease at 45 months’ follow-up consultation.ConclusionThis is a rare report of ovarian carcinosarcoma with an epithelial component composed of squamous cell carcinoma. Combination chemotherapy with paclitaxel and carboplatin may be an effective choice as adjuvant chemotherapy in cases of ovarian carcinosarcoma including squamous cell carcinoma.
Highlights
Ovarian carcinosarcoma, which contains sarcomatous and carcinomatous components, is a very rare tumor
We report a case of ovarian carcinosarcoma in which the carcinomatous component was squamous cell carcinoma
Following debulking surgery for Ovarian carcinosarcoma (OCS), adjuvant chemotherapy is typically recommended
Summary
This is a rare report of OCS with squamous cell carcinoma. In this case, a good course was obtained by complete resection of the tumor and adjuvant combination chemotherapy with carboplatin and paclitaxel. Combination chemotherapy with carboplatin and paclitaxel may be an effective choice as adjuvant chemotherapy in cases of OCS including squamous cell carcinoma. Abbreviations CA125: Cancer antigen 125; CA19–9: Cancer antigen 19–9; CEA: Carcinoembryonic antigen; FIGO: International Federation of Gynecology and Obstetrics; OCS: Ovarian carcinosarcoma; SCC: Squamous cell carcinoma
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have